INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) said the FDA has approved its Verzenio, in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor-positive
Chinese biotechnology company Clover Biopharmaceuticals said on Wednesday that a large trial shows its two-dose COVID-19 vaccine is 79 percent effective against the fast-spreading Delta variant, which was first detected in India.
KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) said the FDA has accepted and granted priority review for a new supplemental Biologics License Application for KEYTRUDA as adjuvant therapy in certain patients
email article
Patients with ultralow-risk breast cancer according to genomic assessment had excellent long-term outcomes regardless of clinical risk or whether they received adjuvant therapy, a new analysis of a randomized trial showed.
The 8-year breast cancer-specific survival (BCSS) was 99.2% among patients classified as clinically high-risk but ultralow-risk by the MammaPrint 70-gene assay. Patients with an ultralow-risk genomic assessment and low clinical risk had an 8-year BCSS of 99.7%. Freedom from distant metastasis at 8 years was 97.6% in patients who were clinically and genomically low-risk versus 95.0% for those who were clinically high-risk but genomically low-risk.
In patients with an ultralow-risk genomic assessment, the 8-year distant metastasis-free interval (DMFI) rate was 97.8% with no adjuvant systemic therapy. That compared with an 8-year DMFI of 97.4% in patients who received only adjuvant endocrine therapy and 94.9% in patients who received chemotherap